What are Novaliq’s products?

Novaliq offers an industry-leading portfolio of new, water-free and IP-protected ophthalmic therapeutics with proven market and clinical success.

What is new about Novaliq’s products?

Novaliq’s IP protected ophthalmic therapeutics can be used in various routes of administration for the transport of drugs for various therapeutic purposes allowing better tolerated, preservative-free formulations for poorly water soluble drugs.

What are the benefits of Novaliq’s products?

Clearly differentiated products based on our water-free EyeSol® drug delivery platform. The key benefits are:

  • Excellent suspendability and solubility of poorly soluble drugs
  • Strong stability enhancement of antibodies, proteins and small molecules
  • Optimal spreading and wetting abilities
  • Strongly enhanced penetration
  • Excellent safety and tolerability profile
  • No preservatives

NovaTears®

NovaTears® is a first-in-class, preservation free eye lubricant for tear film stabilization in evaporative DED.

CyclASol®

CyclASol® is a clear, preservative-free ophthalmic solution of cyclosporine A formulated under clinical evaluation.

NovaTears®+Omega-3

NovaTears®+Omega-3 is a first-in-class, preservative-free and clear eye drop containing 0,2% Omega-3.

Dry Eye Disease

Dry eye disease (DED) is one of the most frequent ocular morbidities and affects a significant percentage…

For which indications are products in development?

Dry Eye Disease (DED), Glaucoma and Retinal Diseases.

What products are next in the pipeline?

  • CyclASol® – a preservative-free, clear cyclosporine A formulation in Phase II, for the treatment of moderate to severe DED.
  • NovaTears®+Omega-3 – a first-in-class, preservative-free and clear eye drop containing 0,2% Omega-3. It stabilizes the lipid layer and reduces the evaporation of the underlying water phase of the tear film.

What clinical trials are currently under way?

  • CyclASol® – a preservative-free, clear cyclosporine A formulation in Phase II for the treatment of moderate to severe DED (CYS-002).
  • NovaTears® – a first-in-class, preservative free ophthalmic artificial tear for patients with mild to moderate dry eye disease (NT-004).
  • MySol™ – a first-in-class, preservative free ophthalmic artificial tear entering clinical trials in the US and Japan to specifically address lipid deficiency in dry eye (NVU-002, FPI expected in 2017).